Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.

Gallicchio L, MacDonald R, Wood B, Rushovich E, Fedarko NS, Helzlsouer KJ.

J Bone Miner Res. 2012 Sep;27(9):1959-66. doi: 10.1002/jbmr.1641.

2.

Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.

Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ.

Climacteric. 2012 Aug;15(4):339-49. doi: 10.3109/13697137.2011.620658. Epub 2011 Dec 23.

PMID:
22191462
3.

A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.

Helzlsouer KJ, Gallicchio L, MacDonald R, Wood B, Rushovich E.

Breast Cancer Res Treat. 2012 Jan;131(1):277-85. doi: 10.1007/s10549-011-1729-2. Epub 2011 Sep 9.

PMID:
21904883
4.

Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.

Gallicchio L, Macdonald R, Wood B, Rushovich E, Helzlsouer KJ.

Breast Cancer Res Treat. 2011 Nov;130(2):569-77. doi: 10.1007/s10549-011-1611-2. Epub 2011 Jun 7.

PMID:
21647676
5.

Supplemental Content

Loading ...
Support Center